178 related articles for article (PubMed ID: 27522673)
1. HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing.
Ruggiero T; Burdino E; Calcagno A; Bonora S; Boglione L; Di Perri G; Ghisetti V
Infection; 2016 Dec; 44(6):789-792. PubMed ID: 27522673
[TBL] [Abstract][Full Text] [Related]
2. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
4. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
[TBL] [Abstract][Full Text] [Related]
5. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.
Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V
Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823
[TBL] [Abstract][Full Text] [Related]
6. Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients.
Bartolini B; Giombini E; Zaccaro P; Selleri M; Rozera G; Abbate I; Comandini UV; Ippolito G; Solmone M; Capobianchi MR
Virus Res; 2013 Nov; 177(2):205-8. PubMed ID: 23954579
[TBL] [Abstract][Full Text] [Related]
7. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
Sede MM; Laufer NL; Quarleri J
Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
[TBL] [Abstract][Full Text] [Related]
8. Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection.
Lieveld FI; Swaans N; Newsum AM; Ho CK; Schinkel J; Molenkamp R; van der Meer JT; Arends JE; Hoepelman AI; Wensing AM; Siersema PD; van Erpecum KJ; Boland GJ
Ann Hepatol; 2016; 15(5):696-704. PubMed ID: 27493108
[TBL] [Abstract][Full Text] [Related]
9. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.
Ogishi M; Yotsuyanagi H; Tsutsumi T; Gatanaga H; Ode H; Sugiura W; Moriya K; Oka S; Kimura S; Koike K
PLoS One; 2015; 10(3):e0119145. PubMed ID: 25748426
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
[TBL] [Abstract][Full Text] [Related]
11. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.
Li Z; Liu Y; Zhang Y; Shao X; Luo Q; Guo X; Lin G; Cai Q; Zhao Z; Chong Y
Biomed Res Int; 2017; 2017():9849823. PubMed ID: 29164151
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.
Jabara CB; Hu F; Mollan KR; Williford SE; Menezes P; Yang Y; Eron JJ; Fried MW; Hudgens MG; Jones CD; Swanstrom R; Lemon SM
Antimicrob Agents Chemother; 2014 Oct; 58(10):6079-92. PubMed ID: 25092699
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
[TBL] [Abstract][Full Text] [Related]
15. Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.
Abdel-Hameed EA; Rouster SD; Zhang X; Chen J; Medvedovic M; Goodman ZD; Sherman KE
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):353-358. PubMed ID: 27898525
[TBL] [Abstract][Full Text] [Related]
16. Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.
Bagaglio S; Messina E; Hasson H; Merli M; Andolina A; Lazzarin A; Uberti-Foppa C; Morsica G
New Microbiol; 2017 Jan; 40(1):53-55. PubMed ID: 28072886
[TBL] [Abstract][Full Text] [Related]
17. Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients.
Abdel-Hameed EA; Rouster SD; Boyce CL; Zhang X; Biesiada J; Medvedovic M; Sherman KE
Dig Dis Sci; 2018 Mar; 63(3):645-652. PubMed ID: 29330726
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
[TBL] [Abstract][Full Text] [Related]
19. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
Treviño A; de Mendoza C; Parra P; Rodríguez C; Madejón A; Plaza Z; del Romero J; Poveda E; Soriano V
Antivir Ther; 2011; 16(3):413-6. PubMed ID: 21555824
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
